Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (309)
- Scheduling (national classification system) (165)
- Advertising (25)
- Safety monitoring and information (23)
- COVID-19 (11)
- Medicinal cannabis hub (6)
- Sunscreens (5)
- Clinical trials (4)
- Compliance and enforcement (4)
- Shortages and supply disruptions (3)
- Legislation (2)
- Breast implant hub (1)
- Cosmetics (1)
- Import and export (1)
- Manufacturing (1)
- Prescription opioids hub (1)
Search
580 result(s) found, displaying 451 to 475
-
Scheduling submissionsPublic submissions on interim scheduling decisions for substances referred to the November 2017 ACMS/ACCS meetings are now available
-
Scheduling decisions (final)Final decisions for substances referred to the ACMS, ACCS/ACMS, ACCS November 2017 meetings, and delegate only decisions on agricultural and veterinary chemicals and NCEs.
-
Corporate reportsReport detailing prescription medicines registrations for 2017
-
Meeting statementsACM 6 meeting statement has been published
-
Meeting statementsACM 7 meeting statement has been published
-
Scheduling submissionsPublic submissions on matters referred to the March 2017 scheduling meetings, and received during the pre-meeting and interim decision consultation periods, are now available
-
Meeting statementsACM 5 meeting statement has been published
-
Meeting statementsACM 2 meeting statement has been published
-
Meeting statementsACM 3 meeting statement has been published
-
Meeting statementsACM 4 meeting statement has been published
-
Scheduling delegates' interim decisions and invitation for further comment: ACCS/ACMS, November 2017
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 5 March 2018 -
Scheduling decisions (final)Scheduling delegates' final decisions: NCEs, January 2017 now published
-
Meeting statementsACV 1 meeting statement has been published
-
Meeting statementsACV 2 meeting statement has been published
-
Corporate reportsThis document reflects the evidence supporting the use of medicinal cannabis in treating chronic pain and the recommendations of the Chronic Pain Working Group
-
Scheduling decisions (final)Final decisions and reasons for matters referred to ACCS#20, ACMS #21 (July 2017 meetings) and Joint ACCS-ACMS #15 and #16 (March and July 2017meetings).
-
Meeting statementsAdvisory Committee on Biologicals (ACB), Meeting 7 statement
-
Meeting statementsAdvisory Committee on Biologicals (ACB), Meeting 8 statement
-
Meeting statementsAdvisory Committee on Biologicals (ACB), Meeting 9 statement
-
Meeting statementsAdvisory Committee on Biologicals (ACB), Meeting 10 statement
-
Meeting statementsAustralian Influenza Vaccine Committee (AIVC) recommendations
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 3 October 2017
-
Meeting statementsACM 1 meeting statement has been published
-
Corporate reportsTGA Stakeholder Survey 2016-17 - questions and answers
-
Scheduling decisions (final)Final decisions for medicines and chemicals referred to March 2017 scheduling meetings (ACMS #20, ACCS #19 and Joint ACMS-ACCS #15) and NCEs.